Friday Mar 14
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of The Medicines Company
A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of The Medicines Company between February 20, 2013 and February 12, 2014, inclusive .
Trending on the Topix Network
Thu Mar 06, 2014
The Medicines Company to Participate in 2014 Barclays Global Healthcare Conference
About The Medicines Company The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide.
Thu Feb 27, 2014
European Medicines Agency Accepts Marketing Authorization Application ...
The Medicines Company today announced that the European Medicines Agency has accepted for review a marketing authorization application for the investigational intravenous antibiotic, oritavancin, for the treatment of complicated skin and skin tissue infections , caused by susceptible gram-positive bacteria, including by methicillin-resistant ... (more)
Tue Feb 25, 2014
The Motley Fool
After Cangrelor, The Medicines Company Gets Priority Review for New Drug
The FDA is set to meet at the end of April, and while the committee's opinion can be disregarded, it appears unlikely that an approval will be granted.
Mon Feb 24, 2014
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against The Medicines Company
The Complaint that defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies.
Wed Feb 19, 2014
The Medicines Company to Participate in Upcoming Healthcare Investor Conferences
Clive Meanwell, MD, PhD, Chairman and CEO, will participate in a question and answer format presentation.
The Motley Fool
Today's Biggest Biotech Stories: Chelsea, Novartis, and The Medicines Company
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
The Medicines Company Reports Fourth Quarter and Full Year 2013 Financial Results
Worldwide net revenue increased by 16% to $185.0 million for the fourth quarter of 2013 from $159.5 million in the fourth quarter of 2012 driven by: Worldwide Angiomax /Angiox revenue, which was up 4% from $155.3 million in 2012 to $160.9 million in 2013, driven by international growth and sustained revenue in the United States .
FDA Accepts Filing of the Medicines Company's New Drug...
The Medicines Company is seeking approval of oritavancin for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus , administered as a single dose.